Prof. Cheung Yin Ting

About me

CHEUNG Yin Ting 張彥婷

B.Sc. (Pharm.) (Hons.), Ph.D.
Assistant Professor
School of Pharmacy
Faculty of Medicine
The Chinese University of Hong Kong

Tel: (852) 3943 6833
Fax:(852) 2603 5295
Email: yinting.cheung@cuhk.edu.hk

Personal Details

Cheung Yin Ting received her B.Sc. (Pharm.) (Hons.) from the National University of Singapore (NUS). She practiced at the Singapore General Hospital before returning to NUS for her postgraduate training. During her Ph.D. candidature, she had the privilege of pioneering the cognitive and psychosocial research program in Asian breast cancer patients. She joined the Department of Epidemiology and Cancer Control at St. Jude Children’s Research Hospital (Memphis, USA) as a Post-Doctoral Research Associate in 2014. Her work with the Cognitive Neuroscience Team at St. Jude involved characterizing the pharmacological, biological and genetic determinants of brain function and other treatment-related complications in survivors of pediatric cancer.

She had previous teaching appointments with Rhodes College (Memphis, USA) as an Adjunct Assistant Professor, and the School of Nursing, Ngee Ann Polytechnic (Singapore) as an Adjunct Associate Lecturer in Pharmacology.

Yin Ting joined the School of Pharmacy at the Chinese University of Hong Kong in August 2017. She hopes that her collaborative research with students, clinicians and scientists can help to improve health outcomes in survivors of cancer and other chronic diseases.

**Seeking motivated MPhil/PhD candidates who wish to pursue a higher degree in cancer survivorship-related research. Learning outcomes include developing integrated skills in epidemiology, biostatistics, pharmacy practice and social sciences. Candidates will have the opportunity to initiate patient-centered outcomes or/and interventional research in a collaborative environment. Please contact Dr Cheung (yinting.cheung@cuhk.edu.hk) for more information. 

Research

Research Interests

Yin Ting’s research interest is in supportive care and survivorship in adult and pediatric oncology.

Major advances in health care delivery have dramatically improved survival rates for children and adults diagnosed with cancer and other life-threatening diseases. Unfortunately, survivorship often comes at a cost of developing a myriad of treatment-related complications that can have a negative impact on their functional outcomes and health-related quality of life.

Yin Ting’s work adopts a combination of epidemiological, translational and qualitative research approaches to characterise these drug-induced toxicities, particularly in adverse outcomes related to brain function, such as neurocognitive impairment, behavioral problems and psychological distress. Her collaborative work involves evaluating how underlying genetic predispositions, as well as physiological biomarkers, biobehavioral factors and chemotherapy exposures during the active treatment phase, are predictive of long-term complications in survivors of cancer.

The eventual goal of this work is to develop an evidence-based model that will facilitate a “personalized survivorship care plan” for each cancer survivor, as well as to apply a similar approach to improve health outcomes in other chronic conditions.

Grants

  • A Biobehavioral Model to Understanding Cognitive and Psychosocial Outcomes in Young Survivors of Childhood Leukemia (ref no: 24614818)
    Sponsored by Research Grant Council (Early Career Scheme) during the period 1-1-2019 to 30-6-2021 for the sum of HKD 636,835
    Role: Principal Investigator
  • Personalized Risk-based Care and Education for Early Survivors of Childhood Cancer in Hong Kong (ref: 03170047)
    Sponsored by Health and Medical Research Fund (Research Fellowship) during the period 1-02-2019 to 31-01-2021 for the sum of HKD 813,070
    Role: Principal Investigator

Teaching

Teaching

Bachelor of Pharmacy Programme

  • PHAR1000 Introduction to Pharmacy
  • PHAR2710 Pharmaceutical Research Methods
  • PHAR4401 Industrial Pharmacy Clerkship: Multi-national Company
  • PHAR4402 Industrial Pharmacy Clerkship: Local Manufacturer
  • PHAR4911 (Research Project I) and PHAR4912 (Research Project II)

Master of Clinical Pharmacy

  • PHAR5852 Pharmacovigilance and Public Health for Pharmacists

Publications

Representative Publications

  1. Cheung YT, Eskind A, Inaba H, Hudson MM, Pui CH, Krull KR, Wolf J. Association of Bacteremic Sepsis With Long-term Neurocognitive Dysfunction in Pediatric Patients With Acute Lymphoblastic Leukemia. JAMA Pediatrics. 2018 Sep 24. doi: 10.1001/jamapediatrics.2018.2500.
  2. Cheung YT, Khan RB, Liu W, Brinkman TM, Edelmann MN, Reddick WE, Pei D, Panoskaltsis-Mortari A, Srivastava D, Cheng C, Robison LL, Hudson MM, Pui CH, Krull KR. Association of Cerebrospinal Fluid Biomarkers of Central Nervous System Injury With Neurocognitive and Brain Imaging Outcomes in Children Receiving Chemotherapy for Acute Lymphoblastic Leukemia. JAMA Oncology 2018 Jul 12;4(7):e180089.
  3. Cheung YT. Cancer Pharmacoethnicity: Ascertaining Chronic Health Outcomes in Survivors of Childhood Cancer in Asia. Global Journal of Pharmaceutical Sciences. 2017; 4(2): 555634.
  4. Cheung YT, Brinkman TM, Li CH, Mzayek Y, Srivastava D, Ness KK, Patel SK, Howell RM, Oeffinger KC, Robison LL, Armstrong GT, Krull KR. Chronic Health Conditions and Neurocognitive Function in Aging Survivors of Childhood Cancer: A Report from the Childhood Cancer Survivor Study. Journal of National Cancer Institute. 2017. 2018;110(4):411-419.
  5. Cheung YT*, Sabin ND*, Reddick WE, Bhojwani D, Liu W, Brinkman TM, Glass JO, Srivastava D, Pui CH, Robison LL, Hudson MM, Krull KR. Leukoencephalopathy and Long-term Neurobehavioural, Neurocognitive, and Brain Imaging Outcomes in Survivors of Childhood Acute Lymphoblastic Leukaemia Treated with Chemotherapy: A Longitudinal Analysis. The Lancet Haematology 2016;3(10):e456-e466 *co-first authors
  6. Krull KR, Cheung YT, Liu W, Fellah S, Reddick WE, Brinkman TM, Kimberg C, Ogg R, Srivastava D, Pui CH, Robison LL, Hudson MM. Chemotherapy Pharmacodynamics, Neuroimaging and Neurocognitive Outcomes in Long-Term Survivors of Childhood Acute Lymphoblastic Leukemia. Journal of Clinical Oncology. 2016;34(22):2644-53
  7. Cheung YT, Krull KR. Neurocognitive Outcomes in Long-term Survivors of Childhood Acute Lymphoblastic Leukemia Treated on Contemporary Treatment Protocols: A Systematic Review. Neuroscience and Biobehavioral Reviews. 2015;53:108-120
  8. Cheung YT, Mulrooney DA, Brinkman TM, Liu W, Banerjee P, Panoskaltsis-Mortari A, Srivastava DK, Pui CH, Robison LL, Hudson MM, Krull KR. Impact of Sleep, Fatigue and Systemic Inflammation on Neurocognitive and Behavioral Outcomes in Long-term Survivors of Childhood Acute Lymphoblastic Leukemia. Cancer 2017 Apr 27. doi: 10.1002/cncr.30742.
  9. Cheung YT, Edelmann MN, Mulrooney DA, Green DM, Chemaitilly W, John N, Robison LL, Hudson MM, Krull KR. Uric Acid and Neurocognitive Function in Survivors of Childhood Acute Lymphoblastic Leukemia Treated with Chemotherapy only. Cancer Epidemiology, Biomarkers & Prevention 2016;25(8):1259-67
  10. Ng T, Teo SM, Yeo HL, Shwe M, Gan YX, Cheung YT, Foo KM, Cham MT, Lee JA, Tan YP, Fan G, Yong WS, Preetha M, Loh WK, Koo SL, Jain A, Lee GE, Wong M, Dent R, Yap YS, Ng R, Khor CC, Ho HK, Chan A. Brain-derived Neurotrophic Factor Genetic Polymorphism (rs6265) is Protective Against Chemotherapy-associated Cognitive Impairment in Patients with Early-stage Breast Cancer. Neuro-Oncology. 2016;18(2):244-51.

 

More Publications

Supplementary Information

Awards

2018 MASCC Rehab, Survivorship QoL SG Successful Training Award – PRO from The Multinational Association of Supportive Care in Cancer (MASCC)
2018 Travel Grant “Mainland and Taiwan Strategic Partnership Development Programme 2018/2019” by Office of Academic Links (China), CUHK
2018 Best Oral Presentation, 8th International Symposium on Cancer Nursing, Hong Kong
Project title: Prevalence of Prescription Psychoactive Medication Use in
Adolescent Survivors of Childhood Cancer: A Report from the Childhood Cancer Survivor Study
2018 Best Poster Award (Student Category) received by BPharm student Jonathan POON Long Hin
8th International Symposium on Cancer Nursing, Hong Kong
Project title: Childhood Cancer Survivorship Work in Asia: A Scoping Review and Directions for Future Research
2017 American Society of Clinical Oncology (ASCO) Meeting 2017, Conquer Cancer Foundation Merit Award
Study title: “Cerebrospinal Fluid (CSF) Markers of Brain Injury and Functional Outcomes in Survivors of Childhood Acute Lymphoblastic Leukemia”
2015 American Society of Hematology (ASH) Meeting 2015, ASH Abstract Achievement Awards and Outstanding Abstract Achievement Awards
Study title: Neurobehavioral and Brain Imaging Outcomes in Survivors of Childhood Acute Lymphoblastic Leukemia Treated with Chemotherapy Only”
2015 American Society of Clinical Oncology (ASCO) Meeting 2015, Conquer Cancer Foundation Merit Award
Study title: Chemotherapy and Brain Function in Long-term Survivors of Childhood Acute Lymphoblastic Leukemia (ALL).”

Media Coverage

MedicalResearch.com. Medical Research Studies with Interviews and News. “Leukoencephalopathy As Marker of Cognitive Impairment After Chemotherapy For Childhood ALL” http://medicalresearch.com/author-interviews/leukoencephalopathy-as-marker-of-cognitive-impairment-after-chemotherapy-for-childhood-all/28527/. 3 October 2016.

Media Release. St Jude Children’s Research Hospital. “Chemo drug makes multitasking a challenge for some leukemia survivors” https://www.stjude.org/research/news-publications/research-highlights/2016-research-highlights/chemo-drug-makes-multitasking-a-challenge-for-some-leukemia-survivors.html. 6 June 2016.

Comments are closed